Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CAR.B7-H3T cells |
Synonyms | |
Therapy Description |
CAR.B7-H3T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3), which potentially induce toxicity in tumor cells expressing CD276 (B7-H3) (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CAR.B7-H3T cells | CAR.B7-H3T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3), which potentially induce toxicity in tumor cells expressing CD276 (B7-H3) (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04670068 | Phase I | CAR.B7-H3T cells Cyclophosphamide + Fludarabine | Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian | Recruiting | USA | 0 |
NCT05366179 | Phase I | CAR.B7-H3T cells | Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc | Recruiting | USA | 0 |